HR Notices From August 25
Visit CBS Detroit's
Tometich named president of Hemlock Semiconductor, Doornbos remains CEO:
Andrew E. Tometich was named president of the entities comprising the Hemlock Semiconductor Group, effective immediately. Richard S. Doornbos remains CEO. Doornbos has provided leadership of Hemlock Semiconductor’s growth since 2006, overseeing more than $4.5 billion of investment and record financial performance. Tometich joined Dow Corning Corp. in 1989, and most recently served as business vice president of strategic feedstocks for Dow Corning’s Core Products Business. He has served on Hemlock Semiconductor’s board of directors since 2010. In his more than 22-year career at Dow Corning, Tometich has served in various commercial, business development and executive positions in the United States and Europe. He has served on the board of directors of several Dow Corning entities and ventures, including West Virginia Alloy L.L.C., Québec Silicon L.L.P., Dow Corning Ltd., Dow Corning Sti Inc. and several Multibase entities. Tometich holds a bachelor’s degree from the University of Notre Dame, a master’s of business administration from the Kellogg School of Management at Northwestern University and has completed formal executive-level studies at INSEAD. More at www.hscpoly.com.
Adeona Appoints George A. Eby to Scientific Advisory Board: Ann Arbor-based Adeona Pharmaceuticals Inc. (NYSE Amex: AEN) announced that it has appointed George A. Eby, a researcher who has conducted multiple clinical studies of zinc lozenges for the common cold, as a member of its Scientific Advisory Board. Eby is a pioneer in the development of zinc lozenges as a treatment for the common cold. He has devoted more than 30 years to the study of zinc and is the executive director of the George Eby Research Institute. He was the first researcher to demonstrate with statistical significance that zinc lozenges can reduce the average duration of symptoms of the common cold by approximately seven days. Eby’s groundbreaking placebo-controlled, randomized, double-blind clinical study was published in the January 1984 volume of American Society for Microbiology and is available at: www.pubmedcentral.nih.gov/picrender.fcgi?artid=185426&blobtype=pdf. His zinc studies have been cited in several journals, most recently in the “Zinc for the Common Cold Review” prepared by The Cochrane Collaboration and “Zinc Lozenges May Shorten the Duration of Colds: A Systematic Review” in The Open Respiratory Medicine Journal, both published during 2011. In July 2011, Adeona acquired exclusive access to two statistically significant clinical studies that demonstrated a reduction in the duration and severity of symptoms associated with the common cold while taking a particular zinc lozenge. Based on the reduction of common cold symptoms shown in these two clinical studies conducted by Ananda S. Prasad, M.D., Ph.D., Adeona intends to commercialize a similar oral zinc lozenge as a homeopathic over-the-counter drug under the brand name wellZin. Plans for manufacturing, packaging and marketing of wellZin are currently under way. More at www.adeonapharma.com.
XanEdu Publishing Names Alar Elken CEO: Ann Arbor-based XanEdu Publishing, Inc. today announced that the company has hired Alar Elken as its new CEO effective Aug. 22. Prior to joining XanEdu, Elken was executive vice president at Cengage Learning. Elken will oversee the company’s global products and services operations, and the organization’s transformational Folio-X e-learning initiative. Elken will also serve as CEO of NA Publishing Inc., under NAPC Holdings LLC which is the company that also owns XanEdu. NA Publishing holds the largest archive of periodicals in microform which it sells to libraries across the world. More at www.xanedu.com.